Everything you need to know about TMS for Treatment-Resistant Depression: What Patients Need to Know — how it works, what it costs, and how to find a provider who actually knows what they're doing.
TMS vs. Medication: A Side-by-Side Guide
Free PDF — compare effectiveness, side effects, cost, and timelines so you can choose with confidence.
Treatment-resistant depression (TRD) is one of the most challenging diagnoses in psychiatry — but it’s also the condition TMS is FDA-cleared to treat. For people who’ve cycled through medication after medication without relief, TMS is a different approach: it uses magnetic pulses to stimulate brain regions involved in mood regulation rather than adjusting brain chemistry.
What You’ll Learn
- The clinical definition of treatment-resistant depression and who qualifies
- Why TMS may help when medications have not
- What research shows about response and remission rates in treatment-resistant populations
- What to expect across the 8-week treatment journey from evaluation to consolidation
- How to maximize your outcome through consistency and lifestyle factors
What Exactly Is Treatment-Resistant Depression?
There’s no single clinical definition, but most psychiatrists consider depression “treatment-resistant” after two or more adequate medication trials fail to produce meaningful improvement. “Adequate” means: the right dose, taken for long enough (typically 6–8 weeks per medication), and often includes different drug classes (SSRIs, SNRIs, atypical agents, augmentation strategies).
Treatment resistance is common: in the large STAR*D study, roughly a third of patients did not reach remission after the first two treatment steps. It’s not a niche condition — it’s a common clinical reality.
Why Standard Treatments Fail in TRD
The brain’s mood-regulation networks — particularly the prefrontal cortex, anterior cingulate, and amygdala — can become progressively less responsive to medication as depression becomes chronic. This isn’t simply a matter of needing higher doses; the neural architecture itself becomes entrenched in patterns that oral medications, which flood the whole brain with chemicals, simply can’t address precisely enough.
TMS takes a different approach: it targets a specific region involved in mood regulation — the left dorsolateral prefrontal cortex (DLPFC) — using magnetic pulses to change its activity.
TMS Response Rates in TRD
Response and remission rates vary by study design and how outcomes are measured:
- Sham-controlled trials: In the NIH-funded OPT-TMS trial of 190 medication-free patients with unipolar depression, remission rates were about 14% with active TMS vs. 5% with sham (George et al., Archives of General Psychiatry, 2010). Response and remission rates are usually higher in real-world settings than in these tightly controlled trials.
- Real-world data: In a naturalistic study of 307 patients treated across 42 US clinical practices, about 58% showed a clinician-rated response and about 37% remitted (Carpenter et al., Depression and Anxiety, 2012, abstract).
- FDA clearance: NeuroStar was cleared in 2008 for adults with major depressive disorder who have not benefited from prior antidepressant medication in the current episode.
Individual results vary, and TMS does not work for everyone.
What to Expect: The Treatment Journey
Week 1–2: Evaluation and Calibration
Before TMS begins, your psychiatrist will conduct a thorough assessment — including a motor threshold determination, where brief magnetic pulses find the smallest intensity that produces a thumb twitch. This calibrates your treatment dose. You’ll also complete baseline mood scales (PHQ-9, MADRS) for tracking progress.
Week 3–6: The Acute Phase
A typical course is about 36 sessions over 6–9 weeks, Monday through Friday. Session length depends on the device and protocol (from a few minutes with theta-burst to roughly 40 minutes), and you remain awake and alert throughout. Many patients begin noticing subjective improvements between weeks 2 and 4. Objective measurement (mood scales) typically shows measurable improvement by week 4.
Week 7+: Consolidation
After acute treatment, most providers recommend tapering: a few sessions per week for 2–4 weeks, then transitioning to a maintenance schedule (monthly boosters or as-needed).
Combining TMS with Medications in TRD
One common question: should you stay on medications during TMS? The evidence is nuanced:
- For most patients: Continuing a current medication during TMS is generally fine, though your psychiatrist will advise on your specific medications
- After TMS: Many patients successfully reduce or discontinue medications — this should be managed by your psychiatrist, never done abruptly
Maximizing Your Outcome
The difference between a “okay” TMS result and an excellent one often comes down to factors patients can control:
- Consistency matters — missing sessions reduces cumulative effect. Plan your schedule around the daily commitment
- Sleep and exercise support overall recovery from depression and are worth maintaining during treatment
- Set realistic expectations — full remission is possible but not guaranteed. A 50% reduction in symptoms is clinically meaningful even if it doesn’t feel “perfect”
- Complete the full course — stopping after 15 sessions because you “feel fine” risks early relapse. Completing the full course is the way TMS is designed to be delivered
Is TMS Right for Your TRD?
If you’ve tried two or more antidepressants without adequate relief, TMS is worth a serious conversation with your psychiatrist. It’s not experimental — it’s FDA-cleared, covered by most major insurers and by Medicare when criteria are met, and has been in clinical use since 2008.
Frequently Asked Questions
How is treatment-resistant depression defined?
Definitions vary, but depression is commonly called treatment-resistant after two or more adequate medication trials fail to produce meaningful improvement. "Adequate" means the right dose taken for long enough (typically 6-8 weeks per medication). Treatment resistance is common: in the large STAR*D study, roughly a third of patients did not reach remission after the first two treatment steps.
What are TMS response rates for treatment-resistant depression?
Response and remission rates vary by study. A naturalistic study of 307 patients treated in 42 US practices reported about 58% clinician-rated response and 37% remission (Carpenter et al., 2012), while sham-controlled trials report lower rates, with remission around 14% in the OPT-TMS trial vs. 5% with sham.
Should I stay on medications during TMS for TRD?
For most patients, continuing a current medication during TMS is generally fine, though your psychiatrist will advise on your specific medications. After TMS, any medication changes should be managed by your psychiatrist and never made abruptly.
Ready to Explore Your TMS Options?
Browse verified TMS providers, read real reviews, and find the right treatment for your situation.
